Envestnet Asset Management
VIR icon

Envestnet Asset Management’s Vir Biotechnology VIR Stock Holding History

Envestnet Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-51,827
Closed -$1.27M – 4168
2023
Q2 		$1.27M Sell
51,827
-292,517
-85% -$7.35M ﹤0.01% 2568
2023
Q1 		$1.05M Buy
344,344
+294,390
+589% +$7.53M ﹤0.01% 2642
2022
Q4 		$1.26M Buy
49,954
+4,733
+10% +$116K ﹤0.01% 2470
2022
Q3 		$872K Buy
45,221
+36,373
+411% +$925K ﹤0.01% 2680
2022
Q2 		$225K Buy
+8,848
New +$207K ﹤0.01% 3516
2022
Q1 		– Sell
-6,839
Closed -$286K – 4070
2021
Q4 		$286K Buy
+6,839
New +$268K ﹤0.01% 3450

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management's VIR Position: Q3 2023 in Review

Envestnet Asset Management sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 51,827 shares — an estimated $1.27M sold.

Envestnet Asset Management first reported a position in VIR in Q4 2021 and held it in 6 quarters. The position peaked at $1.27M in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Envestnet Asset Management reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 51,827 Vir Biotechnology shares in Q3 2023, an estimated $1.27M.
  • Envestnet Asset Management first reported a position in Vir Biotechnology in Q4 2021 and held it in 6 quarters.
  • Envestnet Asset Management's Vir Biotechnology position peaked at $1.27M in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Envestnet Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.